European Archives - Page 464 of 1138 - European Medical Journal

MammaPrint® 10-Year Follow Up Results from a German Breast Cancer Cohort Study

The MammaPrint® (MP) 70-gene test is utilised in personalised treatment planning for patients with early-stage breast cancer (EBC) with either node-positive or node-negative disease and categorises tumours as high risk (MP-HR; MP index: –1–≤0) or low risk (MP-LR; MP index: >0–+1).

Autophagy Flux is Induced in Gastroenteropancreatic Neuroendocrine Neoplasms

Neuroendocrine neoplasms (NEN) represent a rare heterogeneous group with an increasing incidence, consisting of neuroendocrine tumours (NET) and neuroendocrine carcinomas (NEC), mostly prevalent in the gastrointestinal tract. Cancer stage, tumour grade, mode of treatment, and mainly early diagnosis affect overall survival rate.

Following in the footsteps of tech giants

What techniques can pharma companies adopt and adapt from the tech giants dominating the stage of modern-day innovation?

Novartis' Reshema Kemps-Polanco on drive and diversity

What drives Novartis Oncology’s Reshema Kemps-Polanco to succeed?

CT Colonography Versus Optical Colonoscopy: Cost-Effectiveness in Colorectal Cancer Screening

In 2017, colorectal cancer (CRC) accounted for 13% of new malignancy diagnoses in Canada. It is the second leading cause of cancer-related deaths in Canadian males, and the third leading cause of cancer related deaths in Canadian females.

An Unexpected Post-ocrelizumab Improvement in Glycaemic Control in a Patient with Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, causing a plethora of neurological manifestations and a leading cause of non-traumatic disability among young adults.

5 minutes with Anat Cohen-Dayag, CEO, Compugen

Five minutes with Anat Cohen-Dayag, CEO of clinical-stage drug discovery and development company Compugen.

Is the biotech boom on thin ice?

After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future may look more promising.

The Magnificent Surgeon

Jonathan Sackier is joined by Ricky Bhogal, a Consultant at the Royal Marsden Hospital, London, UK, who specialises in Hepato-Pancreato-Biliary Oncology.

Artificially intelligent drug discovery

AI is being implemented into drug development to free up time, money and manpower, but how can humans and computers work together?